急性冠脉综合征患者抗血小板治疗过程中发生上消化道出血的危险因素被引量：1

导出

摘要目的分析急性冠脉综合征患者抗血小板治疗过程中发生上消化道出血的主要危险因素。方法随机的我院2007年1月至2010年1月之间收录的治疗的100例急性冠脉综合征患者分为两组,其中A组患者主要服用阿司匹林与氯吡格雷进行治疗,B组主要服用阿司匹林或者氯吡格雷进行治疗,然后分析两组在进行抗血小板的治疗过程中出现上消化道出血的情况,总结出主要的危险因素。结果其中分析发现,A组患者的上消化道的出血率要高于B组情况,通过资料分析发现阿司匹林与氯吡格雷治疗和患者的年龄>65岁以及服用时间>3个月均为造成上消化道出血的危险因素。结论使用双药(阿司匹林与氯吡格雷)治疗是造成抗血小板的治疗过程中出现上消化道出血的主要因素,同时患者的高龄和长时间的服药以及既往的消化道疾病均可以促进上消化道出血的产生。

作者罗爱华

机构地区新疆维吾尔自治区第二济困医院

出处《中国医药指南》 2013年第2期463-464,共2页 Guide of China Medicine

关键词急性冠脉综合征抗血小板治疗上消化道出血危险因素

分类号 R543 [医药卫生—心血管疾病] R573.2 [医药卫生—消化系统]

引文网络
相关文献

参考文献4

1无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量：2193
2中华医学会心血管病学分会.经皮冠状动脉介入治疗指南[J].中华心血管病杂志,2009,37:2-25.
3周海棠,宋建平.氯吡格雷对急性冠脉综合征血小板活化的干预研究[J].临床和实验医学杂志,2008,7(12):15-17. 被引量：8
4赵嫣,屈百鸣,丁亚辉,俞坚武,车贤达.氯吡格雷和他汀联用对急性冠脉综合征患者临床观察[J].心脑血管病防治,2008,8(5):328-329. 被引量：12

二级参考文献56

1Lawson WE, Hui JC, Lang G. Treatment benefit in the enhanced external counterpulsation consortium. Cardiology, 2000,94 ( 1 ) :31-35.
2Ryden L, Standl E, Bartnic M, et al. Guideline on diabetes, prediabetes and cardiovascular disease:executive summary. The Task Force on Diabetes and Cardiovascular Disease of European Society of Cardiology (ESC) and of the Euopean Association for the Study of Diabetes(EASD). Eur Heart J,2007,28( 1 ) :88-136.
3Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA Guidelines for Ambulatory Electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ( Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology.J Am Coll Cardiol,1999,34(3) :912-948.
4Campeau L. Letter: Grading of angina pectoris. Circulation 1976 :54(3) :522-523.
5O'Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol, 2000,36(1) :326-340.
6Gibbons Pal, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-sunanary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol, 2003,41 ( 1 ) : 159-168.
7Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation, 2004,110(10) :1245-1250.
8Girman CJ, Rhodes T, Mercuri M,et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherescleresis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol,2004,93 ( 2 ) : 136-141.
9Kjekshus JK, Maroko PB, Sobel BE. Distribution of myocardial injury and its relation to epicardial ST-segment changes after coronary artery occlusion in the dog. Cardiovasc Res,1972,6(5) :490-499.
10Kleber AG. ST-segment elevation in the electrocardiogram: a sign of myecaniial iechemia. Cardiovasc Res, 2000,45(1) :111-118.